ArticleFamilial cancer2025
Functional characterization of splice variants in hereditary breast and ovarian cancer susceptibility genes.
Article in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant cancer predisposition syndrome primarily associated with germline mutations in BRCA1 and BRCA2. Nevertheless, the implementation of multigene panels using Next Generation Sequencing (NGS) has expanded the mutational spectrum for this hereditary syndrome. As a result, the number of variants of uncertain clinical significance (VUS) has increased, and their functional and clinical interpretations remains a challenge for genetic counseling. This article reports three splice variants in susceptibility genes detected in women diagnosed with invasive ductal breast cancer. According to in silico predictions, these splicing-disrupting mutations in cancer susceptibility genes are likely to be pathogenic. Splicing functional assays were performed by reverse transcription polymerase chain reaction (RT-PCR) followed by capillary electrophoresis and Sanger sequencing. The characterization of these splicing events has enabled the identification of variants susceptible to alternative or abnormal splicing and their clinical classification according to the consensus criteria of the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP). This research increases our current knowledge about splice variants, thereby improving diagnostic performance and their clinical classification to support appropriate genetic counseling.
Indexed as
Identifiers
41410715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.